Clene Inc. (Nasdaq: CLNN) to present at Emerging Growth Conference on improving mitochondrial health for treating neurodegenerative diseases.
Clene Inc. (Nasdaq: CLNN) announced it, alongside its subsidiary Clene Nanomedicine Inc., will be presenting at the Emerging Growth Conference. The event will focus on the company's efforts to enhance mitochondrial health and safeguard neuronal function to address neurodegenerative ailments like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The conference is scheduled for December 09, 2025, in Salt Lake City, marking a significant step in their clinical-stage biopharmaceutical journey.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments